Quick Answer
BriaCell Therapeutics Corp. reported Cash And Cash Equivalents At Carrying Value of $10.49 million for the year ending 2025.
- BriaCell Therapeutics Corp. showed an increase of +1,117.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from BriaCell Therapeutics Corp.'s annual report (Form 10-K), filed with the SEC on October 16, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2022: $37.45 million | Q1 2023: $33.50 million | Q2 2023: $28.17 million | Q4 2023: $13.65 million | Q1 2024: $6.24 million | Q2 2024: $935.7 thousand | Q4 2024: $5.79 million | Q1 2025: $5.01 million | Q2 2025: $12.46 million | Q3 2025: $10.49 million | Q4 2025: $2.71 million.
- Over the full 5 years of available data (2021 to 2025), BriaCell Therapeutics Corp.'s Cash And Cash Equivalents At Carrying Value has declined by 81.7%.
- Historical annual values: Fiscal year 2025: $10.49 million | Fiscal year 2024: $862.1 thousand | Fiscal year 2023: $21.25 million | Fiscal year 2022: $41.04 million | Fiscal year 2021: $57.27 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: